4th Quarter - Report
W STRATEGIES, LLC for ALEXION PHARMACEUTICALS
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models. Educated staff about access to therapies for rare diseases in Medicaid. March 2016 CMS proposed rule implementing a new Part B drug payment model.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Health Issues HCR
Education about the value of innovative new medicines. H.R. 34: 21st Century Cures Act as it relates to S. 1878: To extend the pediatric priority review voucher program. S. 3056: CREATES Act of 2016.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.